Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 271

Sort by

Sort Order Select

Journal Articles

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

Joseph M. Rocco, Joseph H. Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair, Bita Shakoory, Thomas Robertson, Rachel Dileo, Max W Jacobs, Christa Zerbe, Rachael Gordon, Michael Joseph Ombrello, Amanda K Ombrello, Nirali N Shah, Dimana Dimitrova, Jennifer A Kanakry, Andrew D. Zelenetz, Alison J Moskowitz, Robert N Stuver, Zachary D Epstein-Peterson, Paola Ghione, Elena Mead, Zainab Shahid, Sergio A. Giralt, Sandeep S Raj, Jae H Park, Ivan Maillard, Mark B. Geyer, Wenbin Xiao, Ahmet Dogan, Megan S Lim, Jeffrey I. Zwicker, Jodi V. Mones, Rehka Parameswaran, Lauren G Banaszak, Shamir Geller, Bianca D. Santomasso, Roni Shouval, Kevin J. Curran, Ottavia M Delmonte, Luigi D Notarangelo, Jeffrey I Cohen, Steven M. Holland, Gilles A. Salles, Steven M Horwitz, Santosha A Vardhana, Miguel-Angel Perales, Daniella Schwartz, Irini Sereti, William T. Johnson

Blood blood.2025030976.

https://doi.org/10.1182/blood.2025030976

Published: 2025

Includes: Supplemental data

Journal Articles

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2025-7090

Published: 2025

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation

Brian Shaffer, Amanda Blouin, Candice Rapoport, Deborah Wells, Stephanie Chinapen, Miguel-Angel Perales, Steven Devine, Jeffery Auletta, Heather Stefanski, Stephen Spellman, Martin Maiers

Blood (2025) 146 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2025-2434

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL)

Joseph McGuirk, Miguel-Angel Perales, Mark Fesen, Jeremy Snider, Matt Bye, Anthony Proli, Blythe Adamson, Samuel Hong, Babatunde Adedokun, Hil Hsu

Blood (2025) 146 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2025-4503

Published: 2025

Journal Articles

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Blood (2025) 146 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2025-4498

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Pradipta Ray, Abood Okal, Miguel-Angel Perales, Sandeep Raj, Roni Shouval, Eniko Papp, Sahar Ansari, Krishna R. Juluri, Amanda Przespolewski, Debasmita Roy, Ethan Thompson, Julie A. Rytlewski, Eric Bleickardt, Alessandro Crotta, Timothy B. Campbell, Leanne Peiser

Blood (2025) 146 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2025-3549

Published: 2025

Journal Articles

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 113.

https://doi.org/10.1182/blood-2025-113

Published: 2025

Journal Articles

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tobias Tix, Mohammad Alhomoud, Jaromir Tomasik, Gloria Iacoboni, Edward Cliff, Doris Hansen, Saad Usmani, Gilles Salles, Marion Subklewe, Michael Von Bergwelt, Samuel Yamshon, Miguel-Angel Perales, Roni Shouval, David Cordas Dos Santos, Kai Rejeski

Blood (2025) 146 (Supplement 1): 8135.

https://doi.org/10.1182/blood-2025-8135

Published: 2025

Journal Articles

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2025-6296

Published: 2025

Journal Articles

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Sandeep Raj, Allison Bock, Sharmila Giri, Dilan Patel, Madiha Iqbal, Natalie Grover, Lori Leslie, Marcus Geer, Olalekan Oluwole, Boyu Hu, Grzegorz Nowakowski, Miguel-Angel Perales

Blood (2025) 146 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2025-3748

Published: 2025

Journal Articles

Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM)

Natalia Tijaro Ovalle, Samantha Brown, Amethyst Saldia, Ilan Goldstein, Sean Quach, Natasia Rodriguez, Ioannis Politikos, Miguel-Angel Perales, Glenn Heller, Doris Ponce

Blood (2025) 146 (Supplement 1): 2463.

https://doi.org/10.1182/blood-2025-2463

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 3711.

https://doi.org/10.1182/blood-2025-3711

Published: 2025

Journal Articles

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 1079.

https://doi.org/10.1182/blood-2025-1079

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation

Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL)

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM)

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only